The safety of inactivated influenza vaccines in pregnancy for birth outcomes

a systematic review

Michelle L. Giles, Sushena Krishnaswamy, Kristine Macartney, Allen Cheng

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

Pregnant women are at increased risk of morbidity and mortality from influenza and are recognized as a priority group for influenza vaccination. Despite this, uptake is often poor and one reason cited for this is concerns about safety. The objective of this study was to perform a systematic review of the safety of inactivated influenza vaccination (IIV) in pregnancy. Studies were included if they were: (i) observational or experimental design; (ii) included a comparator group comprising of unvaccinated pregnant women; (iii) comprised of either seasonal IIV or monovalent H1N1 IIV (including adjuvanted vaccines); and (iv) addressed one of the following outcomes: preterm birth (PTB), small for gestational age (SGA), fetal death (including stillbirth or spontaneous abortion), low birth weight (LBW) or congenital abnormalities. Two reviewers screened abstracts and titles and selected full texts for retrieval. Crude odds ratios were calculated from reported event rates, using binomial standard errors. Adjusted odds ratios, hazard ratios and relative rates were extracted as reported in each paper. After removal of duplicates and full text eligibility assessment, 40 studies remained. The aOR for PTB was 0.87 (0.78–0.96), for LBW 0.82 (0.76–0.89), congenital abnormality 1.03 (0.99–1.07), SGA 0.99 (0.94–1.04) and stillbirth 0.84 (0.65–1.08). This study contributes to the increasing body of safety data for IIV in pregnancy and reports a protective effect on PTB and LBW.

Original languageEnglish
Pages (from-to)687-699
Number of pages13
JournalHuman Vaccines & Immunotherapeutics
Volume15
Issue number3
DOIs
Publication statusPublished - 26 Mar 2019

Keywords

  • immunization
  • influenza
  • pregnancy
  • safety
  • vaccination

Cite this

@article{d6289b9d73674f9687a45b4e1ef54f3e,
title = "The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review",
abstract = "Pregnant women are at increased risk of morbidity and mortality from influenza and are recognized as a priority group for influenza vaccination. Despite this, uptake is often poor and one reason cited for this is concerns about safety. The objective of this study was to perform a systematic review of the safety of inactivated influenza vaccination (IIV) in pregnancy. Studies were included if they were: (i) observational or experimental design; (ii) included a comparator group comprising of unvaccinated pregnant women; (iii) comprised of either seasonal IIV or monovalent H1N1 IIV (including adjuvanted vaccines); and (iv) addressed one of the following outcomes: preterm birth (PTB), small for gestational age (SGA), fetal death (including stillbirth or spontaneous abortion), low birth weight (LBW) or congenital abnormalities. Two reviewers screened abstracts and titles and selected full texts for retrieval. Crude odds ratios were calculated from reported event rates, using binomial standard errors. Adjusted odds ratios, hazard ratios and relative rates were extracted as reported in each paper. After removal of duplicates and full text eligibility assessment, 40 studies remained. The aOR for PTB was 0.87 (0.78–0.96), for LBW 0.82 (0.76–0.89), congenital abnormality 1.03 (0.99–1.07), SGA 0.99 (0.94–1.04) and stillbirth 0.84 (0.65–1.08). This study contributes to the increasing body of safety data for IIV in pregnancy and reports a protective effect on PTB and LBW.",
keywords = "immunization, influenza, pregnancy, safety, vaccination",
author = "Giles, {Michelle L.} and Sushena Krishnaswamy and Kristine Macartney and Allen Cheng",
year = "2019",
month = "3",
day = "26",
doi = "10.1080/21645515.2018.1540807",
language = "English",
volume = "15",
pages = "687--699",
journal = "Human Vaccines & Immunotherapeutics",
issn = "2164-5515",
publisher = "Taylor & Francis",
number = "3",

}

The safety of inactivated influenza vaccines in pregnancy for birth outcomes : a systematic review. / Giles, Michelle L.; Krishnaswamy, Sushena; Macartney, Kristine; Cheng, Allen.

In: Human Vaccines & Immunotherapeutics, Vol. 15, No. 3, 26.03.2019, p. 687-699.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The safety of inactivated influenza vaccines in pregnancy for birth outcomes

T2 - a systematic review

AU - Giles, Michelle L.

AU - Krishnaswamy, Sushena

AU - Macartney, Kristine

AU - Cheng, Allen

PY - 2019/3/26

Y1 - 2019/3/26

N2 - Pregnant women are at increased risk of morbidity and mortality from influenza and are recognized as a priority group for influenza vaccination. Despite this, uptake is often poor and one reason cited for this is concerns about safety. The objective of this study was to perform a systematic review of the safety of inactivated influenza vaccination (IIV) in pregnancy. Studies were included if they were: (i) observational or experimental design; (ii) included a comparator group comprising of unvaccinated pregnant women; (iii) comprised of either seasonal IIV or monovalent H1N1 IIV (including adjuvanted vaccines); and (iv) addressed one of the following outcomes: preterm birth (PTB), small for gestational age (SGA), fetal death (including stillbirth or spontaneous abortion), low birth weight (LBW) or congenital abnormalities. Two reviewers screened abstracts and titles and selected full texts for retrieval. Crude odds ratios were calculated from reported event rates, using binomial standard errors. Adjusted odds ratios, hazard ratios and relative rates were extracted as reported in each paper. After removal of duplicates and full text eligibility assessment, 40 studies remained. The aOR for PTB was 0.87 (0.78–0.96), for LBW 0.82 (0.76–0.89), congenital abnormality 1.03 (0.99–1.07), SGA 0.99 (0.94–1.04) and stillbirth 0.84 (0.65–1.08). This study contributes to the increasing body of safety data for IIV in pregnancy and reports a protective effect on PTB and LBW.

AB - Pregnant women are at increased risk of morbidity and mortality from influenza and are recognized as a priority group for influenza vaccination. Despite this, uptake is often poor and one reason cited for this is concerns about safety. The objective of this study was to perform a systematic review of the safety of inactivated influenza vaccination (IIV) in pregnancy. Studies were included if they were: (i) observational or experimental design; (ii) included a comparator group comprising of unvaccinated pregnant women; (iii) comprised of either seasonal IIV or monovalent H1N1 IIV (including adjuvanted vaccines); and (iv) addressed one of the following outcomes: preterm birth (PTB), small for gestational age (SGA), fetal death (including stillbirth or spontaneous abortion), low birth weight (LBW) or congenital abnormalities. Two reviewers screened abstracts and titles and selected full texts for retrieval. Crude odds ratios were calculated from reported event rates, using binomial standard errors. Adjusted odds ratios, hazard ratios and relative rates were extracted as reported in each paper. After removal of duplicates and full text eligibility assessment, 40 studies remained. The aOR for PTB was 0.87 (0.78–0.96), for LBW 0.82 (0.76–0.89), congenital abnormality 1.03 (0.99–1.07), SGA 0.99 (0.94–1.04) and stillbirth 0.84 (0.65–1.08). This study contributes to the increasing body of safety data for IIV in pregnancy and reports a protective effect on PTB and LBW.

KW - immunization

KW - influenza

KW - pregnancy

KW - safety

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85057531551&partnerID=8YFLogxK

U2 - 10.1080/21645515.2018.1540807

DO - 10.1080/21645515.2018.1540807

M3 - Article

VL - 15

SP - 687

EP - 699

JO - Human Vaccines & Immunotherapeutics

JF - Human Vaccines & Immunotherapeutics

SN - 2164-5515

IS - 3

ER -